Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Vicuron Charts. Click Here for more Vicuron Charts.](/p.php?pid=staticchart&s=N%5EMICU&p=8&t=15)
Vicuron Pharmaceuticals Announces Data at ICAAC Supporting
Next-Generation Lincosamide Program
Lead Product Candidate to Enter Clinic in the First Half of Next Year
KING OF PRUSSIA, Pa., Nov. 1 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals
Inc. (Nasdaq: MICU; Nuovo Mercato) today announced that research generated from
its internal discovery program supports further development of VIC-5555, its
lead novel lincosamide. This next generation clindamycin antibiotic, a part of
an ongoing lincosamide program, has demonstrated improved in vivo efficacy,
potency and dosing. The strong array of preclinical data was presented at the
44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) meeting in Washington, D.C. this past weekend.
"Although the data is early, we believe it shows the promise of the lincosamide
program to address anaerobic infections and again demonstrate Vicuron's
internal research engine's strength in producing promising product candidates,"
Richard J. White, Ph.D., Chief Scientific Officer of Vicuron. "We expect to
move the initial product candidate from this program into the clinic in the
first half of next year. We feel that our approach to discovery will continue
to yield promising next-generation compounds for both hospital-based and
community-acquired infections."
Highlights of the oral presentation and nine poster presentations indicated
that the company's lead lincosamide product candidate, VIC-5555, has:
- good in vitro activity; and
- excellent in vivo properties including superior efficacy over
clindamycin in experimental Staphylococcus aureus, Steptoccus pneumoniae
and Bacteroides fragilis.
About Lincosamide Program
Vicuron is developing next-generation lincosamides, a class of antibiotics
which show excellent anaerobe and Gram-positive activity. The current
lincosamide of choice is clindamycin which requires dosing two to four times a
day and shows poor activity against enterococci. VIC-5555 is the lincosamide
program's most advanced next-generation clindamycin. It has potential for
improved efficacy and potency with an improved dosing regimen. This product
candidate has potential applications in primary hospital indications such as
intraabdominal and skin and soft tissue infections.
About Vicuron
Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, manufacturing and commercializing vital medicine for seriously ill
patients. In May 2004, Vicuron received an approvable letter from the FDA for
its lead product anidulafungin for the treatment of esophageal candidiasis.
The company's other lead product, dalbavancin, a novel intravenous antibiotic
for the treatment of serious Gram-positive infections, has completed Phase 3
clinical trials. The company's versatile research engine integrates
industry-leading expertise in functional genomics, natural products discovery,
mechanism-based drug design and combinatorial and medicinal chemistry. These
approaches are yielding promising novel and next- generation compounds, many of
which are in the later stages of preclinical development. In addition, the
company has research and development collaborations with leading pharmaceutical
companies, such as Pfizer and Novartis.
Forward-Looking Statements
This news release contains forward-looking statements that predict or describe
future events or trends. The matters described in these forward- looking
statements are subject to known and unknown risks, uncertainties and other
unpredictable factors, many of which are beyond Vicuron's control. Vicuron
faces many risks that could cause its actual performance to differ materially
from the results predicted by its forward-looking statements, including the
possibilities that clinical trials and the results thereof might be delayed, or
unsuccessful, that the timing of the filing of any new drug application or any
amendment to a new drug application might be delayed, that clinical trials
might indicate that a product candidate is unsafe or ineffective, that the FDA
might require additional information to be submitted and additional actions to
be taken before it will make any decision, that any filed new drug application
may not be approved by the FDA, that ongoing proprietary and collaborative
research might not occur or yield useful results, that the pipeline may not
yield a new clinical candidate or a commercial product, that a third party may
not be willing to license our product candidates on terms acceptable to us or
at all, that competitors might develop superior substitutes for Vicuron's
products or market these competitive products more effectively, that a sales
force may not be developed as contemplated and that one or more of Vicuron's
product candidates may not be commercialized successfully. The reports that
Vicuron files with the U.S. Securities and Exchange Commission contain a fuller
description of these and many other risks to which Vicuron is subject. Because
of those risks, Vicuron's actual results, performance or achievements may
differ materially from the results, performance or achievements contemplated by
its forward- looking statement. The information set forth in this news release
represents management's current expectations and intentions. Vicuron assumes no
responsibility to issue updates to the forward-looking matters discussed in
this news release.
DATASOURCE: Vicuron Pharmaceuticals Inc.
CONTACT: Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals Inc.,
+1-610-205-2312, or ; or Hala Mirza of WeissComm
Partners, +1-212-204-2080, or , or Aline Schimmel of
Burns McClellan Inc., +1-212-213-0006, or , both for
Vicuron Pharmaceuticals Inc.
Web site: http://www.vicuron.com/